Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis
Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Imran Alibhai, Ph.D. as Chief Executive Officer and a member of the Board of Directors, effective immediately. “After a competitive national search, we are delighted to welcome Dr. Alibhai to Tvardi,” said Ron Read More
Tvardi is pleased to announce that Jim Allison, Scientific Advisory Board Member of the company, has just won the Nobel Prize. The Nobel Prize in physiology or medicine was awarded Monday morning, October 1, 2018, to cancer researchers James P. Allison and Tasuku Honjo whose studies led to the development of drugs that unleash the Read More
Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million Series A financing round. Series A funding is expected to enable the completion of ongoing Phase 1 studies for Tvardi’s lead compound TTI-101 in solid tumor cancers, and the completion of Read More